NS Healthcare is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
White Paper
April 14, 2016
Based on its cutting-edge microjet reactor (MJR) technology platform, leon-nanodrugs is on its way to becoming one of the leading companies in the reformulation arena for poorly soluble or non-soluble oral and parenteral drugs. Dr Wolfgang Beier, CSO and co-founder of leon, answers World Pharmaceutical Frontiers’ questions.
Download to find out more.